• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

    15.75 -0.03 (-0.19%)
    Streaming Delayed Price Updated: 10:47 AM EST, Feb 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 229,619
    Open 15.77
    Bid (Size) 15.75 (100)
    Ask (Size) 15.78 (100)
    Prev. Close 15.78
    Today's Range 15.63 - 16.49
    52wk Range 8.180 - 22.50
    Shares Outstanding 47,147,781
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
    Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
    Via The Motley Fool
    News headline image
    Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
    This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    -12.8%
    -12.8%
    1 Month
    -15.1%
    -15.1%
    3 Month
    -8.2%
    -8.2%
    6 Month
    +62.9%
    +62.9%
    1 Year
    -6.6%
    -6.6%

    More News

    Read More
    News headline image
    Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Nurix Therapeutics Inc (NASDAQ:NRIX) Reports Mixed Q4 2025 Results, Highlights Key Clinical Milestone ↗
    Via Chartmill
    Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip ↗
    Via Stocktwits
    News headline image
    Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
    Via Chartmill
    News headline image
    Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
    From Equity Insider
    Via GlobeNewswire
    News headline image
    13 Analysts Have This To Say About Nurix Therapeutics ↗
    Via Benzinga
    News headline image
    Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
    Via MarketMinute
    News headline image
    Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views ↗
    Via Benzinga
    News headline image
    Nurix Therapeutics Posts Downbeat Q3 Results, Joins Orthopediatrics, Levi Strauss And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday ↗
    Via Benzinga
    News headline image
    NURIX THERAPEUTICS INC (NASDAQ:NRIX) Misses Q3 2025 Estimates, Shares Drop ↗
    Via Chartmill
    News headline image
    6 Analysts Assess Nurix Therapeutics: What You Need To Know ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving after the closing bell on Thursday? ↗
    Via Chartmill
    News headline image
    A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts ↗
    Via Benzinga
    News headline image
    Amazon To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments ↗
    Via Stocktwits
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Nurix Therapeutics, Inc. - Common stock publicly traded?
    Yes, Nurix Therapeutics, Inc. - Common stock is publicly traded.
    What exchange does Nurix Therapeutics, Inc. - Common stock trade on?
    Nurix Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Nurix Therapeutics, Inc. - Common stock?
    The ticker symbol for Nurix Therapeutics, Inc. - Common stock is NRIX on the Nasdaq Stock Market
    What is the current price of Nurix Therapeutics, Inc. - Common stock?
    The current price of Nurix Therapeutics, Inc. - Common stock is 15.75
    When was Nurix Therapeutics, Inc. - Common stock last traded?
    The last trade of Nurix Therapeutics, Inc. - Common stock was at 02/23/26 10:47 AM ET
    What is the market capitalization of Nurix Therapeutics, Inc. - Common stock?
    The market capitalization of Nurix Therapeutics, Inc. - Common stock is 742.58M
    How many shares of Nurix Therapeutics, Inc. - Common stock are outstanding?
    Nurix Therapeutics, Inc. - Common stock has 743M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.